Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs - PubMed (original) (raw)

Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs

K M Messenger et al. J Vet Pharmacol Ther. 2012 Oct.

Abstract

The objective of this study was to determine the pharmacokinetics (PK) of enrofloxacin in pigs and compare to the tissue interstitial fluid (ISF). Six healthy, young pigs were administered 7.5 mg/kg enrofloxacin subcutaneously (SC). Blood and ISF samples were collected from preplaced intravenous catheters and ultrafiltration sampling probes placed in three different tissue sites (intramuscular, subcutaneous, and intrapleural). Enrofloxacin concentrations were measured using high-pressure liquid chromatography with fluorescence detection, PK parameters were analyzed using a one-compartment model, and protein binding was determined using a microcentrifugation system. Concentrations of the active metabolite ciprofloxacin were negligible. The mean ± SD enrofloxacin plasma half-life, volume of distribution, clearance, and peak concentration were 26.6 ± 6.2 h (harmonic mean), 6.4 ± 1.2 L/kg, 0.18 ± 0.08 L/kg/h, and 1.1 ± 0.3 μg/mL, respectively. The half-life of enrofloxacin from the tissues was 23.6 h, and the maximum concentration was 1.26 μg/mL. Tissue penetration, as measured by a ratio of area-under-the-curve (AUC), was 139% (± 69%). Plasma protein binding was 31.1% and 37.13% for high and low concentrations, respectively. This study demonstrated that the concentration of biologically active enrofloxacin in tissues exceeds the concentration predicted by the unbound fraction of enrofloxacin in pig plasma. At a dose of 7.5 mg/kg SC, the high tissue concentrations and long half-life produce an AUC/MIC ratio sufficient for the pathogens that cause respiratory infections in pigs.

PubMed Disclaimer

Cited by

Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift.
Wang S, Huang A, Gu Y, Li J, Huang L, Wang X, Tao Y, Liu Z, Wu C, Yuan Z, Hao H. Wang S, et al. Antibiotics (Basel). 2022 Mar 17;11(3):403. doi: 10.3390/antibiotics11030403. Antibiotics (Basel). 2022. PMID: 35326865 Free PMC article.
Effects of Temperature on Plasma Protein Binding Ratios (PPBRs) of Enrofloxacin and Ciprofloxacin in Yellow Catfish (Pelteobagrus fulvidraco), Grass Carp (Ctenopharyngodon idella), and Largemouth Bass (Micropterus salmoides).
Xu N, Sun W, Zhang H, Li Z, Luo X, Ai X, Ding Y, Cheng B. Xu N, et al. Animals (Basel). 2023 May 25;13(11):1749. doi: 10.3390/ani13111749. Animals (Basel). 2023. PMID: 37889633 Free PMC article.
Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets.
Nixon E, Almond GW, Baynes RE, Messenger KM. Nixon E, et al. Front Vet Sci. 2020 Feb 20;7:82. doi: 10.3389/fvets.2020.00082. eCollection 2020. Front Vet Sci. 2020. PMID: 32154277 Free PMC article.
Efficacy of enrofloxacin in a mouse model of sepsis.
Slate AR, Bandyopadhyay S, Francis KP, Papich MG, Karolewski B, Hod EA, Prestia KA. Slate AR, et al. J Am Assoc Lab Anim Sci. 2014 Jul;53(4):381-6. J Am Assoc Lab Anim Sci. 2014. PMID: 25199094 Free PMC article.
Enrofloxacin Poisoning: A Rare Occurrence in Children.
Senapati BC, Vyasam S, Prasad S, Sekhar JC, Angurana SK. Senapati BC, et al. Indian J Pediatr. 2023 Mar;90(3):306. doi: 10.1007/s12098-022-04450-3. Epub 2023 Jan 10. Indian J Pediatr. 2023. PMID: 36624327 No abstract available.

Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs - PubMed (original) (raw)